Publications

Below is a list of research papers which have been funded (in part, or wholly) by Bright Red. Please click the links below for further information.

Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia

Human dendritic cell deficiency: the missing ID?

Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency

IRF8 mutations and human dendritic-cell immunodeficiency

The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency

Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation

Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study

A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation

The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics

Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone–rituximab refractory patients

Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future

Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies

A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2

CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia